User:Mr. Ibrahem/Daridorexant

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Daridorexant
Clinical data
Trade namesQuviviq
Other namesNemorexant; ACT-541468, Daridorexant hydrochloride (USAN US)
AHFS/Drugs.comMonograph
License data
Addiction
liability		Some[1]
Routes of
administration		By mouth[2]
Drug classOrexin receptor antagonist
Legal status
Legal status
Pharmacokinetic data
Bioavailability62%[2]
Protein binding99.7%[2]
MetabolismExtensive (mainly CYP3A4 (89%))[2]
Onset of actionTmax: 1–2 hours (delayed by 1.3 hours with food)[2]
Elimination half-life8 hours (6–10 hours)[2][4]
Duration of action~8 hours (50 mg)[4]
ExcretionFeces: ~57%[2]
Urine: ~28%[2]
Identifiers
  • [(2S)-2-(5-Chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone
Chemical and physical data
FormulaC23H23ClN6O2
Molar mass450.93 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl
  • InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1
  • Key:NBGABHGMJVIVBW-QHCPKHFHSA-N

Daridorexant, sold under the brand name Quviviq, is a medication used to treat trouble sleeping.[3] It is used in those who have had problems for at least three months and is only recommended short term.[3] It is taken by mouth half an hour before bed.[2][3]

Common side effects include headache, sleepiness, and tiredness.[2] Other side effects may include depression, sleep paralysis, and complex sleep behavior.[2] It has a relatively low risk of misuse.[2][5] It should not be used in those with severe liver problems or narcolepsy.[2] Safety in pregnancy is unclear.[1] It is a dual orexin receptor antagonist (DORA) and works by blocking the action of orexin.[3] It is not a benzodiazepine or Z-drug.[6]

Daridorexant was approved for medical use in the United States and Europe in 2022.[2][3] In the United States a month of medication costs about 470 USD as of 2022.[7] It is not commercially available in the United Kingdom as of 2022.[8] It is a schedule IV controlled substance in the United States.[2]

References[edit]

  1. ^ a b "Daridorexant Monograph for Professionals". Drugs.com. Retrieved 10 December 2022.
  2. ^ a b c d e f g h i j k l m n o p q r "Quviviq- daridorexant tablet, film coated". DailyMed. 23 March 2022. Archived from the original on 19 September 2022. Retrieved 18 September 2022.
  3. ^ a b c d e f g "Quviviq EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 4 May 2022. Retrieved 5 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. ^ a b Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.
  5. ^ "Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV". Archived from the original on 13 April 2022. Retrieved 13 April 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  6. ^ Roch C, Bergamini G, Steiner MA, Clozel M (October 2021). "Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia". Psychopharmacology (Berl). 238 (10): 2693–2708. doi:10.1007/s00213-021-05954-0. PMC 8455402. PMID 34415378.
  7. ^ "Daridorexant". Retrieved 10 December 2022.
  8. ^ "Daridorexant". SPS - Specialist Pharmacy Service. 13 April 2019. Archived from the original on 17 May 2022. Retrieved 10 December 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Daridorexant&oldid=1209968838"